Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Uses "Unusual" Action To Get Matrixx's Zicam Off The Market

This article was originally published in The Tan Sheet

Executive Summary

In a rare action, FDA simultaneously alerted consumers not to use Matrixx Initiatives' intranasal Zicam products because of potential safety problems and warned Matrixx to remove the products from market without first consulting with the firm

You may also be interested in...



Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO

Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.

Zicam Marketer Matrixx Tabs Another Pharma Consumer Health Veteran As CEO

Private equity firm Gryphon Investments appoints Marc Rovner, with executive experience at Pfizer, Reckitt, Unilever and BI, to helm the Zicam brand homeopathic cold remedy marketer in a shakeup that also puts consumer health care industry veterans at lead posts for sales, marketing and strategy.

TheraBiogen Supports Theramax Expansion With Education Push

Homeopathic firm TheraBiogen plans to roll out products “every six to nine months” to add to its existing lineup of homeopathic remedies for allergy and cold and flu, says CEO Kelly Hickel. The firm also counts on sales growth from a social media campaign to explain what is not in its products as well as what is.

Related Content

Topics

UsernamePublicRestriction

Register

PS103065

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel